Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4898 Target Snapshot

BDNF/NT-3 growth factors receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,630Compounds
535Assays
22Approved Drugs
2,034.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

BDNF/NT-3 growth factors receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16620. Start with cancer, then reuse UniProt Q16620 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt Q16620 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

BDNF/NT-3 growth factors receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats BDNF/NT-3 growth factors receptor as ChEMBL target CHEMBL4898, mapped to UniProt Q16620. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
BDNF/NT-3 growth factors receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4898
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16620
BDNF/NT-3 growth factors receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether BDNF/NT-3 growth factors receptor is the right protein anchor across sources, using UniProt Q16620 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBDNF/NT-3 growth factors receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ16620
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBDNF/NT-3 growth factors receptor
UniProt AccessionQ16620
Component TypeProtein
Sequence Length822 aa

BDNF/NT-3 growth factors receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as BDNF/NT-3 growth factors receptor, mapped to UniProt Q16620. Sequence length is 822 aa.

Mapped IDQ16620
Review nameBDNF/NT-3 growth factors receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

BDNF/NT-3 growth factors receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREPOTRECTINIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREPOTRECTINIB
Late clinical Phase III
acute lymphoblastic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLESTAURTINIB
Late clinical Phase III
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREPOTRECTINIB
Clinical signal Phase II
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLESTAURTINIB
Clinical signal Phase II
essential thrombocythemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLESTAURTINIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

22
Approved
9
Phase III
23
Phase II
8
Phase I
Assay Mix

Activity Type Distribution

IC50912.0
KI957.0
EC5024.0
KD141.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4298138 10.3 IC50 0.05 Approved
CHEMBL388978 10.2 IC50 0.0636 Preclinical
CHEMBL3673452 10.0 IC50 0.1 Clinical
CHEMBL6044141 9.74 Kd 0.18 Preclinical
CHEMBL3678285 9.7 IC50 0.2 Preclinical
CHEMBL3678283 9.7 IC50 0.2 Preclinical
CHEMBL3673480 9.7 IC50 0.2 Preclinical
CHEMBL3673479 9.7 IC50 0.2 Preclinical
CHEMBL3673477 9.7 IC50 0.2 Preclinical
CHEMBL3673453 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

72
5.0
107
5.5
141
6.0
162
6.5
140
7.0
141
7.5
112
8.0
62
8.5
72
9.0
45
9.5
pChEMBL
Approved Drugs

Approved Drugs

REPOTRECTINIB
CHEMBL4298138
Approved 2023
Properties Compare Identifier
QUIZARTINIB
CHEMBL576982
Approved 2023
Properties Compare Identifier
ENTRECTINIB
CHEMBL1983268
Approved 2019
Properties Compare Identifier
LAROTRECTINIB
CHEMBL3889654
Approved 2018
Properties Compare Identifier
LAROTRECTINIB SULFATE
CHEMBL3989939
Approved 2018
Properties Compare Identifier
LORLATINIB
CHEMBL3286830
Approved 2018
Properties Compare Identifier
MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
CRIZOTINIB
CHEMBL601719
Approved 2011
Properties Compare Identifier
RUXOLITINIB
CHEMBL1789941
Approved 2011
Properties Compare Identifier
NILOTINIB
CHEMBL255863
Approved 2007
Properties Compare Identifier
SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
Assay Landscape

Assay Landscape

535
Total Assays
587
Tested Compounds
3
Assay Types
Binding — 528 assays, 587 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 397 324 7.6
cell-based format 79 226 5.9
assay format 52 37 7.6
ADME — 5 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 7 6.7
cell-based format 2 4 6.5
single protein format 1 0 —
Functional — 2 assays, 250 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 250 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine